Wyeth, Catalyst Sign Agreement To Develop, Commercialize Factor VIIa Products

Published: 30-Jun-2009

Wyeth to support the discovery, research and preclinical development

Wyeth and Catalyst have entered into a collaboration for the discovery, development and commercialization of Factor VIIa products, to treat hemophilia and other bleeding conditions.

Under the collaboration, Wyeth will support the discovery, research and preclinical development by Catalyst of Factor VIIa products, including CB 813, Catalyst’s investigational candidate drug. It is intended for the treatment and prophylaxis of acute bleeding in patients with hemophilia.

The company said that the tenure of the exclusive research portion of the collaboration is two years, and may be extended by Wyeth for up to three additional years.

According to the terms of the agreement, Catalyst will receive support for up to twelve full-time employees. Wyeth will be responsible for the development, manufacturing and worldwide commercialization of products resulting from the collaboration.

In addition, during the research term, Wyeth would have the right of first negotiation for any additional clotting factors discovered by Catalyst to treat hemophilia and other bleeding conditions.

Total payments under the collaboration, including an upfront payment of $21 million, research funding and milestone payments, could exceed $500 million, exclusive of royalty payments.

Nassim Usman, CEO of Catalyst, said: “We are thrilled to join forces with Wyeth, a biopharmaceutical company at the forefront of both hemophilia treatment and the development and commercialization of biologic therapies.”

“This collaboration highlights the value Catalyst has created in our Factor VIIa portfolio of products. Revenues generated from research collaborations such as this one allow us to continually expand and support existing discovery efforts around bleeding disorder product candidates and the engineering of new Alterase therapeutic products,” he added.

Tell your friend about this article